FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006141228> ?p ?o ?g. }

• W2006141228 endingPage "2113" @default.
• W2006141228 startingPage "2107" @default.
• W2006141228 abstract "Adjuvant BEP (bleomycin, etoposide, cisplatin) is effective treatment for high-risk clinical stage I (HRCS1) non-seminomatous germ cell tumours (NSGCT), but the known toxicities of etoposide, and the expansion of the HR group to any patient with vascular invasion (50% of patients), led the Medical Research Council to pilot the BOP regimen. Patients received two courses of BOP 14 days apart: cisplatin 50 mg m(-2) days 1 and 2, vincristine 1.4 mg m(-2) (max. 2 mg) days 2 and 8, bleomycin 30,000 IU days 2 and 8. Primary outcome was relapse rate; quality of life, fertility, hearing and lung function were assessed pre- and post-treatment. In all, 100 patients were required. A total of 115 eligible patients were registered, all received two courses of chemotherapy. Median follow-up is 70 months; two relapses have occurred and the 5-year relapse-free rate is 98.3% (95% confidence interval (CI) 95.5%, 99.9%). As assessed by clinicians during treatment, complete (reversible) alopecia was present in 20% of patients; World Health Organization (WHO) grade 1/2 neurotoxicity was present in 41%/5% of patients during treatment and 22%/1% at 6 months. However, 12% of patients reported 'quite a bit' or 'very much' pain/numbness/tingling in hands/feet 2 years after chemotherapy. Mature follow-up confirms high efficacy for two courses of cisplatin-based adjuvant chemotherapy in HRCS1 NSGCT. Substituting vincristine for etoposide decreases alopecia, but gives a low incidence of significant neuropathy. There are no clearcut advantages to 2 x BOP over 2 x BEP, except for patients who wish to maximise the chance of avoiding significant alopecia." @default.
• W2006141228 created "2016-06-24" @default.
• W2006141228 creator A5023188445 @default.
• W2006141228 creator A5025921361 @default.
• W2006141228 creator A5029086118 @default.
• W2006141228 creator A5040028722 @default.
• W2006141228 creator A5051555348 @default.
• W2006141228 creator A5062762491 @default.
• W2006141228 creator A5062805582 @default.
• W2006141228 creator A5066576612 @default.
• W2006141228 creator A5069707508 @default.
• W2006141228 creator A5072381271 @default.
• W2006141228 creator A5082102746 @default.
• W2006141228 creator A5090337382 @default.
• W2006141228 date "2005-05-31" @default.
• W2006141228 modified "2023-10-06" @default.
• W2006141228 title "Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17)" @default.
• W2006141228 cites W178076140 @default.
• W2006141228 cites W1804445123 @default.
• W2006141228 cites W1866911875 @default.
• W2006141228 cites W2008270150 @default.
• W2006141228 cites W2008984621 @default.
• W2006141228 cites W2014374128 @default.
• W2006141228 cites W2019842572 @default.
• W2006141228 cites W2048392832 @default.
• W2006141228 cites W2052137772 @default.
• W2006141228 cites W2108522817 @default.
• W2006141228 cites W2166035874 @default.
• W2006141228 cites W2220613250 @default.
• W2006141228 cites W2279427630 @default.
• W2006141228 cites W2323139555 @default.
• W2006141228 cites W4232182820 @default.
• W2006141228 cites W4362231427 @default.
• W2006141228 cites W44254208 @default.
• W2006141228 doi "https://doi.org/10.1038/sj.bjc.6602624" @default.
• W2006141228 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2361823" @default.
• W2006141228 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15928672" @default.
• W2006141228 hasPublicationYear "2005" @default.
• W2006141228 type Work @default.
• W2006141228 sameAs 2006141228 @default.
• W2006141228 citedByCount "72" @default.
• W2006141228 countsByYear W20061412282012 @default.
• W2006141228 countsByYear W20061412282013 @default.
• W2006141228 countsByYear W20061412282014 @default.
• W2006141228 countsByYear W20061412282015 @default.
• W2006141228 countsByYear W20061412282016 @default.
• W2006141228 countsByYear W20061412282017 @default.
• W2006141228 countsByYear W20061412282018 @default.
• W2006141228 countsByYear W20061412282019 @default.
• W2006141228 countsByYear W20061412282020 @default.
• W2006141228 countsByYear W20061412282021 @default.
• W2006141228 countsByYear W20061412282022 @default.
• W2006141228 crossrefType "journal-article" @default.
• W2006141228 hasAuthorship W2006141228A5023188445 @default.
• W2006141228 hasAuthorship W2006141228A5025921361 @default.
• W2006141228 hasAuthorship W2006141228A5029086118 @default.
• W2006141228 hasAuthorship W2006141228A5040028722 @default.
• W2006141228 hasAuthorship W2006141228A5051555348 @default.
• W2006141228 hasAuthorship W2006141228A5062762491 @default.
• W2006141228 hasAuthorship W2006141228A5062805582 @default.
• W2006141228 hasAuthorship W2006141228A5066576612 @default.
• W2006141228 hasAuthorship W2006141228A5069707508 @default.
• W2006141228 hasAuthorship W2006141228A5072381271 @default.
• W2006141228 hasAuthorship W2006141228A5082102746 @default.
• W2006141228 hasAuthorship W2006141228A5090337382 @default.
• W2006141228 hasBestOaLocation W20061412281 @default.
• W2006141228 hasConcept C126322002 @default.
• W2006141228 hasConcept C141071460 @default.
• W2006141228 hasConcept C143998085 @default.
• W2006141228 hasConcept C2776232574 @default.
• W2006141228 hasConcept C2776694085 @default.
• W2006141228 hasConcept C2776755627 @default.
• W2006141228 hasConcept C2776938808 @default.
• W2006141228 hasConcept C2778119113 @default.
• W2006141228 hasConcept C2778336483 @default.
• W2006141228 hasConcept C2779429289 @default.
• W2006141228 hasConcept C2781413609 @default.
• W2006141228 hasConcept C71924100 @default.
• W2006141228 hasConceptScore W2006141228C126322002 @default.
• W2006141228 hasConceptScore W2006141228C141071460 @default.
• W2006141228 hasConceptScore W2006141228C143998085 @default.
• W2006141228 hasConceptScore W2006141228C2776232574 @default.
• W2006141228 hasConceptScore W2006141228C2776694085 @default.
• W2006141228 hasConceptScore W2006141228C2776755627 @default.
• W2006141228 hasConceptScore W2006141228C2776938808 @default.
• W2006141228 hasConceptScore W2006141228C2778119113 @default.
• W2006141228 hasConceptScore W2006141228C2778336483 @default.
• W2006141228 hasConceptScore W2006141228C2779429289 @default.
• W2006141228 hasConceptScore W2006141228C2781413609 @default.
• W2006141228 hasConceptScore W2006141228C71924100 @default.
• W2006141228 hasIssue "12" @default.
• W2006141228 hasLocation W20061412281 @default.
• W2006141228 hasLocation W20061412282 @default.
• W2006141228 hasLocation W20061412283 @default.
• W2006141228 hasLocation W20061412284 @default.
• W2006141228 hasOpenAccess W2006141228 @default.
• W2006141228 hasPrimaryLocation W20061412281 @default.
• W2006141228 hasRelatedWork W2019842572 @default.

• next